Introduction
The conference "Application of Molecular Biomarkers in Epidemiology," was held at the National Institute of Environmental Health Sciences, February 21-22, 1990 . The primary objective ofthe conference was to provide an up-to-date review of some of the molecular biomarkers currently available in order to promote discussion between laboratory scientists and epidemiologists on the utility ofthese biomarkers. Biomarkers are indicators of molecular and cellular events in biological systems that may allow epidemiologists and other health professionals to better examine the relationships between environmental hazards and human health effects. Biomarkers fall into three basic categories: biomarkers ofdose, effect, and susceptibility. Many laboratories are using molecular biology and sophisticated chemical techniques to develop such biomarkers, but their application in epidemiological studies has been quite limited so far. The current and future use of biomarkers in epidemiological studies at Superfund sites and in the workplace was discussed.
This conference report is formatted somewhat differently from the other reports ofthe Superfund Basic Research Program in its series of conferences in 1990. The biomarkers conference was different in its presentation in that the series of short talks by the participants were used as discussion points to be expanded at the various round tables. The conference consisted of six sessions of 15-min presentations and two round-table discussions. On the first day, there were two sessions on biomarkers of carcinogenesis and biomarkers ofchemical exposure, which were followed by a round-table discussion on the usefulness of these biomarker methods in epidemiology. A further session of talks on correlation studies in animal models followed. On the second day, there were three sessions of 15-min talks followed by a 2 hr round-table discussion at the end ofthe day. The first two sessions described biomarkers of individual phenotypic variability and biomarkers ofhealth effects other than cancer, and the last session focused on the current use ofbiomarkers in epidemiological studies. A summary of the conference program is provided in the Appendix.
Biomarkers of Carcinogenesis
The first session was chaired by M. T. Smith (University of California, Berkeley) and . B. Weinstein (ColumbiaUniversity). Smith began the session by recounting recent progress in our understanding of the cancer process and the implied lessons for biomarkers. Work by Vogelstein and others clearly indicates that genetic alterations occur throughout the cancer process. Moreover, these genetic changes are not only point mutations, but chromosome-wide events such as aneuploidy-induction and translocations. Screening chemicals for their ability to induce genetic damage should therefore involve looking at many different end points.
Molecular biology advances should allow investigators to evaluate chemicals much more rapidly than current cytogenetic approaches. W. Thilly (Massachusetts Institute ofTechnology) characterized an approach that involves the use of a high-fidelity polymerase chain reaction and denaturing gradient gel electrophoresis. This method allows his group to amplify specific segments of DNA (e.g. an exon or coding region of the gene coding for hypoxanthine-guanine phosphoribosyl transferase; hprt) and to study the spectrum ofmutations produced by chemical exposure and by spontaneous/background events. Thilly described mutational spectra produced by various chemicals including hydrogen peroxide and spontaneous events, and showed how they differ markedly. He suggested that this rapid and simple methodology could be used on large numbers ofpeople, individually and as pooled samples, to identify mutational spectra characteristic of particular chemical exposures. Thilly's approach of looking directly at the genotype differs from, but is complementary to, that taken by R. Albertini (University ofVermont), who addressed the selection of lymphocytes with a mutant phenotype resulting from changes in their hprt gene. These lymphocytes can then be analyzed for the nature His group has thus measured adducts formed between styrene oxide and hemoglobin or albumin in the blood of styrene-exposed workers. Using data from both in vitro and in vivo experiments, Raney determined the amount of alkylation by styrene oxide. He calculated that the method he described could detect exposures between 0.4 and 4.0 ppm in workers and approximately 0.2-2.0 ppm in the general population, The method, which should be applicable to many other chemicals, is being refined to improve sensitivity.
DNA-protein crosslinks are a major form of genetic damage that can be readily analyzed. M. Costa (New York University) illustrated that in cells exposed to cisplatinum or chromium VI, four major proteins were complexed to the DNA. Costa's group has unambiguously identified the protein crosslinked to the DNA as actin, based on proteolytic maps, reaction with an actin antibody, and alterations in restriction enzyme digestion of DNA containing the crosslinked protein. However, when cells are exposed to formaldehyde, histones, not actin, are complexed to the DNA. Thus, particular classes of chemicals may produce different protein-DNA crosslinks. In addition to being a promising biomarker of exposure, DNA-protein crosslinking is a major form of genetic damage and one that persists during cell proliferation. Costa suggested this approach could be used to identify exposure to particular groups of toxic chemicals and also delineated a new technology for measuring DNA-protein crosslinks that relies on SDS-PAGE gel electrophoresis and electroblotting.
Recounting his experience in measuring DNA adducts in human populations, K. Hemminki (University of Helsinki) described using the 32P-postlabeling procedure and immunoassays to determine the formation of DNA adducts in Finnish foundry workers. Rather than absolute quantitation of polycyclic aromatic hydrocarbon (PAH) DNA adduct formation, he used a score of adduct formation to express his results. He gave the foundry workers a 2.1 adduct score. After vacation, they had a 1.0 adduct score, demonstrating that adduct levels were transient and stable for only approximately 1 month. Hemminki then compared PAH-DNA adducts in Polish foundry workers and in local and rural residents. The score in local residents was almost as high as in the foundry workers, both of which were significantly higher than in the rural area. This emphasizes the importance ofassessing background environmental exposure in any studies of worker populations. He further stated that quantitative aspects of 32P-postlabeling were not sufficiently studied and described the difficulties in producing quantitative numbers with these methods. 32P-postlabeling can best be used to assess relative exposures rather than absolute levels of exposure/dose.
Urinary metabolites can also be used to assess chemical exposures. While these may be transient in nature, it is important to note that a large majority of chemicals are converted mainly to urinary metabolites, which makes this relatively simple screening approach widely applicable.
A. Buckpitt (University of California, Davis) defined the potential for monitoring naphthalene exposure through urinary metabolites. Because the IS,2R epoxide ofnaphthalene is the major binding species and pulmonary toxicant, Buckpitt related the importance of screening for the IS, 2R mercapturic acid in urine when quantitating the biologically important dose of naphthalene. By comparing it to the 1R,2S levels, one can determine the ability of people to convert naphthalene to an active metabolite capable of causing injury to the lung.
Round- Table Discussion 1 The charge to the first round- 
Biomarkers of Individual Phenotypic Variability
The second day began with descriptions of several new ways of assessing differences in the ability of humans to metabolize various chemicals, either to toxic or nontoxic products. There are substantial differences in the levels of particular enzymes involved in the metabolism of chemicals in people. These differences seem to be related to both genetic and environmental influences. Especially interesting were the depictions of noninvasive methods allowing epidemiologists to characterize a given individual's ability to metabolize certain groups ofchemicals. An example ofthis was the method related by M. A. Butler (National Center for Toxicologic Research), which requires humans to drink coffee and then have their urine analyzed for the manner in which they metabolize caffeine. This has been found to be associated with their levels of cytochrome P-450 IA2, which demethylates caffeine at the 3-position to 1,7-dimethylxanthine. By determining the ratio of this 1,7-metabolite to others in the urine, it is possible to assess an individual's P-450 IA2 activity level. This is important because this P450 enzyme catalyzes the first step of arylamine activation to metabolites that are carcinogenic in the bladder. Studies in Italian and Chinese populations have shown a bimodal distribution of activity with < 30% of the populations having high P-450 IA2 activity. Studies are underway to determine if workers who developed bladder cancer from exposure to arylamines are rapid caffeine metabolizers with high P-450 1A2 activity.
F. P. Guengerich (Vanderbilt University) recounted how more than 20 cDNA sequences were known for human cytochrome P-450s, but three seem to predominate in their importance in the activation ofprocarcinogens. These were P-450 IA2, discussed above, which is also called P-450PA and activates phenacetin, arylamines, and food pyrolysis products; P-450 IIIA4, also called P-45ONF, which metabolizes nifedipine, aflatoxins, polycyclic dihydrodiols, and 6-aminochrysene; and P-450 IIE1, also called P-450j, which metabolizes ethanol, benzene, alkylnitrosamines, and chlorinated hydrocarbons. These P-450s are inducible ( In animal studies it has been possible to determine the amount ofparticulates that deposit on the bifurcations of alveolar ducts. Whether such markers could be useful for human studies is difficult to predict. By using autoradiography it is also possible to measure cell proliferation in the lung and to predict which cell populations are the first to respond to particulates and noxious agents. For further information on biomarkers of pulmonary toxicity, readers are referred to the National Research Council monograph (1) .
Liver damage and subsequent cell proliferation could be measured by release of certain liver-specific growth factors into the bloodstream. G. Michaelopoulos (Duke University Medical Center) delineated how, for example, hepatopoietin A is a 100,000 molecular weight liver cell mitogen and growth factor that is released into the blood during regenerative cell growth after liver damage. An ELISA assay has been developed to measure this factor in blood, which may be a highly sensitive biomarker of subtle damage and hepatic cell proliferation.
Use of Biomarkers in Epidemiology Studies
The final session ofthe conference concentrated on the current use ofbiomarkers in epidemiological studies. Case histories of the use of biomarkers such as protein adducts, DNA adducts, sister chromatid exchange (SCE), and micronuclei were recounted. S. Tannenbaum (Massachusetts Institute of Technology) began the session by characterizing the use of hemoglobin adducts to assess exposure to arylamines such as 4-aminobiphenyl (ABP). Working together with epidemiologists from the National Cancer Institute and the University of Turin, Italy, his group has shown that ABP adduct levels are higher in smokers ofblack tobacco (as opposed to blonde tobacco), which is associated with a higher risk of bladder cancer. Moreover, in all groups, including nonsmokers, they found about a 50% higher adduct level in persons of the slow acetylator phenotype. The adduct level was therefore affected by the type of tobacco smoked and the individual's acetylator phenotype. F. Perera (Columbia University) presented a series of large ongoing epidemiological studies, the objective of which is to correlate various biomarkers of exposure, effect, and susceptibility in humans exposed to styrene, aminobiphenyl, ethylene oxide, and polycyclic aromatic hydrocarbons. Similarly, J. Yager (Electrical Power Research Institute) reported on a study performed on styrene-exposed workers in Washington State. Extensive industrial hygiene measurements of worker dosimetry were performed on this population so that correlations could be made between worker exposure and various biomarkers. The biomarkers studied included DNA adducts, hemoglobin adducts, and SCE and micronuclei formation in peripheral lymphocytes. Only SCE induction data were fully analyzed at the time of the meeting, and Yager delineated statistical approaches to determining the relative contributions of styrene exposure, cigarette smoking, age, and other factors. An approximate 10% chemically related increase in SCE levels can be measured by this approach with statistical significance in 20-40 individuals.
Round- Table Discussion 2 In the final 2 hr of the conference, a second round-table discussion was held. A group of eight epidemiologists and a group of laboratory scientists were assembled. Both groups were asked to respond to two questions: How can current biomarkers be used most effectively? What new types of biomarkers need to be developed?
M. Schenker (University of California, Davis) started the discussion by emphasizing the need for biomnarkers of exposure because of the importance of ascertaining exposures in epidemiological studies. L. Fine (National Institute of Occupational Safety and Health) followed with comments about how biomarkers ofexposure could be used in intervention studies to test the effectiveness of particular control strategies. He then raised an ethical concern regarding the misuse ofbiomarkers of susceptibility, cautioning that these biomarkers could potentially and incorrectly serve as a screening mechanism to exclude groups of workers from the workplace. Fine concluded his remarks by pointing out that many occupational and environmental studies are now evaluating nonclassical exposures, such as those from electrical fields, and that biomarkers need to be developed that can evaluate these kinds of exposures.
C. Shy (University of North Carolina, Chapel Hill) focused the discussion on ways of evaluating the effectiveness of using biomarkers in field investigations. The feasibility of biomarkers as an epidemiological tool could only be determined, for example, when the following information is known: what types of samples need to be collected; how much of the samples can be stored; and how long the samples can be stored. Shy raised questions about study and research design that he felt would also have to be clarified, including determination ofthe size ofthe sample required in order to have sufficient power, whether serial sampling would be necessary, the associated costs of carrying out the studies, and the level of expertise required both in the field and in the laboratory. Finally, Shy emphasized the need to correlate biomarkers with the standard techniques currently used to evaluate exposures and the need for "gold standards" to assess their validity.
The importance of correlating the presence or level of a particular biomarker with a clinical outcome was highlighted by H. Checkoway (University ofWashington). Through such correlation, the significance ofdetecting a change in a biomarker could be ascertained. His remarks were followed by J. Andrews (Agency for Toxic Substances and Disease Registry), who counseled investigators to use biomarkers in field studies so that the validity, sensitivity, and usefulness ofthe studies could be determined. A. Caporaso (National Cancer Institute) Emphasizing the necessity of developing predictive biomarkers and urging that the scientific community not settle for poorly characterized markers, C. Harris (National Cancer Institute) pointed out that such research efforts will require a large expenditure of funds. He called for continued investigation into molecular mechanisms in developing biomarkers ofeffect for cancer. It is his opinion that investigators should focus future efforts on tumor-suppressor genes, not activated oncogenes, and concentrate on developing technologies for markers ofeffect in this area. He was confident that these tools would be forthcoming but that they would involve sophisticated techniques and would be expensive. Harris ended with remarks about our growing understanding ofgenetic predisposition as a factor affecting an individual's risk of disease and reiterated earlier comments about the ethical issues that are raised surrounding potential worker discrimination issues.
The need to incorporate relevant biomarkers into monitoring and animal studies and to have these studies examine different end points todetermine ifthebiomarkers arepredictive inthese models was the focus ofYager's comments. She also raised the question ofhow to determine when an assay is robust enough (i.e., predictable enough, sensitive enough, specific enough) to be used.
Finally, she underscored the need to identify the sources ofbiological variability in the development and application ofbiomarkers. 
